The Onchocerciasis Elimination Program for the Americas (OEPA)

  title={The Onchocerciasis Elimination Program for the Americas (OEPA)},
  author={Mauricio Sauerbrey},
  journal={Annals of Tropical Medicine \& Parasitology},
  pages={25 - 29}
  • M. Sauerbrey
  • Published 1 September 2008
  • Medicine, Political Science
  • Annals of Tropical Medicine & Parasitology
Abstract Human onchocerciasis (river blindness) occurs in 13 foci distributed among six countries in Latin America (Brazil, Colombia, Ecuador, Guatemala, Mexico and Venezuela), where about 500,000 people are considered at risk. An effort to eliminate the disease from the region was launched in response to a specific resolution adopted by the PanAmerican Health Organization (PAHO) in 1991: to eliminate onchocerciasis from the region, as a public-health problem, by 2007. The effort took advantage… 
Progress toward elimination of onchocerciasis in the Americas.
The OEPA's success has had a great influence on programs in Africa, especially Sudan and Uganda, which moved from a control to an elimination strategy in 2006 and 2007, respectively, and the successes in the Americas have greatly influenced WHO guidelines for onchocerciasis transmission elimination.
Onchocerciasis in the Americas: from arrival to (near) elimination
The lessons learned through the efforts in the Americas are in turn informing the program to control and eliminate onchocerciasis in Africa, but continued support and investment are needed for program implementation and post-treatment surveillance to protect the gains to-date and ensure complete elimination is achieved.
A Roadmap Followed: The Path Towards the Elimination of Onchocerciasis in Latin America
Onchocerciasis, a chronic, debilitating, poverty-promoting parasitic disease, is one of the five most common of the officially designated neglected tropical diseases. It has been found in 13 discrete
Progress Toward Elimination of Onchocerciasis in the Americas — 1993–2012
  • Medicine
    MMWR. Morbidity and mortality weekly report
  • 2013
Transmission of the infection had been interrupted or eliminated in four of the six endemic countries in the WHO Americas Region by the end of 2012, and only 4% of the 560,911 persons originally at risk in the Americas will be under ivermectin MDA in 2013.
Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world
The empirical evidence of the elimination of Onchocerca volvulus transmission by Simulium exiguum after 12 years of 6-monthly mass drug administration of Mectizan® (ivermectin) to all the eligible residents living in this endemic area is provided.
Elimination of onchocerciasis in Africa by 2025: the need for a broad perspective
Programmatic treatment and evaluation approaches, pioneered in the Americas, are the most efficient among the existing tools for elimination, and their broader use could catalyze the successful elimination of this disease in Africa.
Importance of ivermectin to human onchocerciasis: past, present, and the future.
Current research needs and control methods by which the public health community in endemic countries may respond to resistance, should it occur in their area, are discussed, along with the continuing importance of this anthelmintic as the mainstay in onchocerciasis control programs.
Assessment and monitoring of onchocerciasis in Latin America.
Interruption of Onchocerca volvulus transmission in Northern Venezuela
Empirical evidence is provided of interruption of Onchocerca volvulus transmission by Simulium metallicum in 510 endemic communities from two Northern foci of Venezuela, after 10–12 years of 6-monthly Mectizan® (ivermectin) treatment to all the eligible residents.
Evidence of suppression of onchocerciasis transmission in the Venezuelan Amazonian focus
Evidence of recent transmission and morbidity suppression in some communities of the focus representing 75% of the Yanomami population and 70 % of all known communities means that onchocerciasis transmission could be feasibly interrupted in the Venezuelan Amazonian focus.


The Onchocerciasis Elimination Program for the Americas: a history of partnership.
  • J. Blanks, F. Richards, M. Jacox
  • Political Science
    Revista panamericana de salud publica = Pan American journal of public health
  • 1998
The decision in 1987 by the pharmaceutical firm Merck & Co. to provide Mectizan (ivermectin) free of charge to river blindness control programs has challenged the international public health
Short report: impact of ivermectin community-level treatments on elimination of adult Onchocerca volvulus when individuals receive multiple treatments per year.
  • E. Cupp, M. Cupp
  • Medicine
    The American journal of tropical medicine and hygiene
  • 2005
A reanalysis of several published reports indicates that when community-wide biannual treatment disrupts transmission of new infection, a profound macrofilaricidal effect of ivermectin (Mectizan)
Certification of Elimination of Human Onchocerciasis: Criteria and Procedures
  • Document WHO/CDS/CPE/CEE/ 2001.18b. Geneva: WHO.
  • 2001
The Onchocerciasis Elimination Program
  • 1998